| Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review H Siebinga, MDM Stokkel, ADR Huitema, JJMA Hendrikx Theranostics 12 (18), 7804, 2022 | 25 | 2022 |
| A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors H Siebinga, BJ de Wit-van der Veen, JH Beijnen, MPM Stokkel, ... EJNMMI research 11, 1-12, 2021 | 14 | 2021 |
| The impact of peptide amount on tumor uptake to assess PSMA receptor saturation on 68Ga-PSMA-11 PET/CT in patients with primary prostate cancer H Siebinga, J olde Heuvel, EJ Rijkhorst, JJMA Hendrikx Journal of Nuclear Medicine 64 (1), 63-68, 2023 | 10 | 2023 |
| Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of 177Lu‐PSMA‐617 in prostate cancer patients H Siebinga, BM Privé, SMB Peters, J Nagarajah, TPC Dorlo, ... CPT: Pharmacometrics & Systems Pharmacology 12 (8), 1060-1071, 2023 | 7 | 2023 |
| The effect of long-acting somatostatin analogues on the uptake of [177Lu]Lu-HA-DOTATATE CHAM Veerman, H Siebinga, DMV de Vries-Huizing, MET Tesselaar, ... European Journal of Nuclear Medicine and Molecular Imaging 50 (5), 1434-1441, 2023 | 7 | 2023 |
| A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients H Siebinga, BJ de Wit-van der Veen, JH Beijnen, TPC Dorlo, ... EJNMMI research 13 (1), 8, 2023 | 4 | 2023 |
| Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population … H Siebinga, BJ de Wit-van der Veen, JH Beijnen, MPM Stokkel, ... EJNMMI physics 10 (1), 48, 2023 | 3 | 2023 |
| Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough H Siebinga, CHAM Veerman, L de Wit-van der Veen, MPM Stokkel, ... EJNMMI research 12 (1), 74, 2022 | 3 | 2022 |
| Population pharmacokinetic evaluation and optimization of amikacin dosage regimens for the management of mycobacterial infections H Siebinga, F Robb, AH Thomson Journal of Antimicrobial Chemotherapy 75 (10), 2933-2940, 2020 | 3 | 2020 |
| The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy H Siebinga, JJMA Hendrikx, DMV de Vries-Huizing, ADR Huitema, ... European Journal of Nuclear Medicine and Molecular Imaging 51 (3), 820-827, 2024 | 2 | 2024 |
| Quantification of biochemical PSA dynamics after radioligand therapy with [177Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model H Siebinga, BJ de Wit-van der Veen, DMV de Vries-Huizing, WV Vogel, ... EJNMMI physics 11 (1), 39, 2024 | 1 | 2024 |
| Predicting the effect of different folate doses on [68Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling H Siebinga, JJMA Hendrikx, ADR Huitema, BJ de Wit-van der Veen EJNMMI research 13 (1), 60, 2023 | 1 | 2023 |
| A Population Pharmacokinetic Study to Evaluate Doxorubicin Exposure Across All Age Groups MI Mohmaed Ali, AL Nijstad, RJ Boosman, MR Crombag, S Barnett, ... Clinical Pharmacokinetics 63 (12), 1711-1722, 2024 | | 2024 |
| Pharmacokinetic analysis of 177Lu-DOTATATE using Mixed model across treatment cycles A Akhavanallaf, A Golzaryan, M Clark, H Siebinga, J Hendrikx, B Viglianti, ... EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 51, S292-S292, 2024 | | 2024 |
| 363P Palbociclib exposure in relation to response and toxicity in patients with advanced breast cancer SM Buijs, MIM Ali, E Oomen-de Hoop, CL Braal, N Wortelboer, ... Annals of Oncology 35, S369, 2024 | | 2024 |
| Pharmacometric approaches to improve theranostics H Siebinga Utrecht University, 2023 | | 2023 |
